Latest from Fox Chase

Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.
Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.
Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.
Alexander Kutikov, MD, has been appointed the new chief of the Division of Urologic Oncology at Fox Chase Cancer Center.
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the phase Ib trial of epacodostat and pembrolizumab (Keytruda) in patients with urothelial carcinoma.
Elizabeth Plimack, MD, recaps recent advances in bladder cancer and discusses the need for diverse approaches to further improve patient outcomes.
Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses the updated findings of the KEYNOTE-045 trial of pembrolizumab (Keytruda) in urothelial carcinoma.
Publication Bottom Border
Border Publication